Illumina (ILMN) Set to Announce Earnings on Thursday

Illumina (NASDAQ:ILMN) is scheduled to release its earnings data after the market closes on Thursday, May 2nd. Analysts expect Illumina to post earnings of $0.03 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The business had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The company’s revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the business posted $0.14 EPS. On average, analysts expect Illumina to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Illumina Stock Performance

NASDAQ ILMN opened at $122.87 on Thursday. The stock has a 50-day simple moving average of $132.44 and a two-hundred day simple moving average of $127.54. The firm has a market capitalization of $19.57 billion, a P/E ratio of -16.74 and a beta of 1.19. Illumina has a fifty-two week low of $89.00 and a fifty-two week high of $228.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66.

Analyst Ratings Changes

ILMN has been the subject of several recent analyst reports. TD Cowen lowered Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target for the company. in a research note on Thursday, January 4th. Stephens restated an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research note on Wednesday, April 10th. HSBC cut Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Finally, OTR Global reiterated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $167.70.

Insider Transactions at Illumina

In related news, CEO Jacob Thaysen acquired 7,330 shares of the business’s stock in a transaction dated Thursday, February 22nd. The shares were acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the transaction, the chief executive officer now owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.17% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.